LUNG CANCER: Studies of patient biopsies and preclinical models imply that activating EGFR mutations drive an immunosuppressive tumour microenvironment, and suggest synergy for combination EGFR/PD-1 inhibition.

Web

Feb. 17, 2020

SCIENTIFIC

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer.

Science Immunology, Jan 31th 2020

https://immunology.sciencemag.org/content/5/43/eaav3937/tab-pdf